Köpf-Maier P
Institut für Anatomie, Freie Universität Berlin, Germany.
J Struct Biol. 1990 Oct-Dec;105(1-3):35-45. doi: 10.1016/1047-8477(90)90096-u.
In the present study, the intracellular localization of titanium was analyzed in three xenografted human adenocarcinomas of the colon sigmoideum (S 90), the stomach (M-Stg 4), and the lung (L 261) in dependence on the time after application of a single therapeutic dose (80 mg/kg) of the organometallic antitumor agent titanocene dichloride (C5H5)2TiCl2. The investigations were performed by use of electron energy loss spectroscopy (EELS), a method which allows microanalysis in ultrathin sections, in combination with electron spectroscopic imaging (ESI), which offers the possibility to image the two-dimensional localization and distribution of light- and medium-weight elements in animal tissues. In all three tumors which were studied, titanium was at first detected within the nucleus and, some hours and days later, it was additionally found in cytoplasmic lysosomes. In the colon and lung tumors S 90 and L 261, already 12 hr after treatment, titanium was traceable as tender granules in the nuclear chromatin. During the following days, it was then accumulated in certain areas of the nuclear heterochromatin and, in the case of the L 261 tumor, also in the nucleolus. Maximum concentrations were attained in the nuclei and nucleoli at 48 hr after substance application. Thereafter, titanium was increasingly incorporated into cytoplasmic lysosomes which are known to be involved in intracellular degrading and digesting processes and which occurred in increased numbers in treated tumor cells. Regarding the stomach carcinoma M-Stg 4, titanium was recognized in the nuclear heterochromatin only 1 and 2 days after application of titanocene dichloride. At 48 hr, it was additionally detected in cytoplasmic lysosomes. In all cases where titanium was found accumulated in the nucleus and in lysosomes, phosphorus was simultaneously enriched in a similar local distribution and a concentration which even exceeded that within phosphorus-rich areas, e.g., the nuclear heterochromatin and cytoplasmic ribosomes. These results confirm a primary interaction of titanium-containing metabolites deriving from titanocene complexes with nucleic acid molecules, especially with nuclear DNA. They suggest the formation of aggregates between nucleic acids and titanium-containing metabolites which are obviously extruded out of the nuclei and incorporated into cytoplasmic lysosomes, known to be involved in intracellular digesting processes.
在本研究中,依据单次治疗剂量(80毫克/千克)的有机金属抗肿瘤剂二氯二茂钛((C5H5)2TiCl2)给药后的时间,分析了钛在三种异种移植的人类乙状结肠癌(S 90)、胃癌(M-Stg 4)和肺癌(L 261)中的细胞内定位。研究采用电子能量损失谱(EELS)进行,该方法可对超薄切片进行微分析,并结合电子光谱成像(ESI),后者能够对动物组织中轻、中重量元素的二维定位和分布进行成像。在所研究的所有三种肿瘤中,最初在细胞核内检测到钛,数小时和数天后,在细胞质溶酶体中也发现了钛。在结肠癌和肺癌S 90和L 261中,治疗后12小时,钛就可作为细小颗粒在核染色质中检测到。在接下来的几天里,它在核异染色质的某些区域积累,在L 261肿瘤中,也在核仁中积累。给药后48小时,在细胞核和核仁中达到最大浓度。此后,钛越来越多地被纳入细胞质溶酶体,已知细胞质溶酶体参与细胞内降解和消化过程,且在经治疗的肿瘤细胞中数量增加。对于胃癌M-Stg 4,仅在应用二氯二茂钛1天和2天后,在核异染色质中识别出钛。48小时时,在细胞质溶酶体中也检测到了钛。在所有发现钛在细胞核和溶酶体中积累的情况下,磷同时以相似的局部分布和浓度富集,其浓度甚至超过富含磷的区域,如核异染色质和细胞质核糖体中的浓度。这些结果证实了源自二茂钛络合物的含钛代谢物与核酸分子,特别是与核DNA的主要相互作用。它们表明核酸与含钛代谢物之间形成了聚集体,这些聚集体显然从细胞核中挤出并纳入细胞质溶酶体,已知细胞质溶酶体参与细胞内消化过程。